Radiation Therapy Trial Shows Promise for Breast Cancer
A clinical study has successfully expanded after meeting initial goals for delaying therapy changes in patients.
Updated on Oct. 5, 2026 in Cancer
Live Poll
Do you prefer cancer treatments that extend current therapies over those that switch medications sooner?
A clinical trial testing stereotactic body radiation therapy (SBRT) has expanded following a successful initial enrollment phase. Researchers are evaluating whether ablating progressing lesions can allow patients with metastatic breast cancer to maintain their current systemic treatment for at least six months.
Why it matters
By targeting specific progressing lesions with radiation, the study aims to extend the effectiveness of existing systemic medications. This approach could provide a new strategy for managing metastatic disease while delaying the need to transition to more aggressive treatment lines.
The study met its stage-one threshold with 4 out of 8 initial patients remaining on systemic therapy for 6 months, exceeding the 2-patient requirement. The trial aims for a 50% success rate across a planned maximum enrollment of 18 participants.
The players
ASTRO
The American Society for Radiation Oncology is a professional medical organization that hosts an annual meeting where researchers share findings on radiation therapies.
The details
The trial enrolls patients with ER-positive metastatic breast cancer who have between one and four progressing lesions and are on their first to third line of systemic therapy. Researchers use FES PET imaging to monitor estrogen receptor activity while applying SBRT to ablate the progressing sites.
Timeline
Patients must remain on their current systemic therapy for 6 months post-SBRT as the primary outcome measure.
Preliminary findings were presented at the ASTRO meeting in October 2026.
The Big Picture
This study follows an established trend in oncology research focusing on the FES PET imaging biomarker to track estrogen receptor activity. It integrates these imaging metrics to determine if localized radiation can effectively influence the systemic progression of metastatic breast cancer.
This trial offers a potential strategy for patients to remain on their current medication longer by specifically targeting new tumor growth. Participants and their oncology teams may eventually gain a new option to preserve the utility of their existing systemic therapy regimens.
The takeaway
Targeted radiation therapy may offer a way to manage metastatic breast cancer without immediately escalating systemic drug treatments. This research highlights the shift toward using localized interventions to maintain the effectiveness of existing medication cycles.
Further reading
Learn more about the latest research and clinical approaches in Cancer.
Source note: This article includes information reported by Pharmacytimes.
Live Poll
Do you prefer cancer treatments that extend current therapies over those that switch medications sooner?
